- Home
- MGLD vs SER Comparison
MGLD vs SER Comparison
Compare MGLD & SER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGLD
- SER
- Stock Information
- Founded
- MGLD 1996
- SER 2017
- Country
- MGLD United States
- SER United States
- Employees
- MGLD N/A
- SER N/A
- Industry
- MGLD Finance/Investors Services
- SER Biotechnology: Pharmaceutical Preparations
- Sector
- MGLD Finance
- SER Health Care
- Exchange
- MGLD Nasdaq
- SER Nasdaq
- Market Cap
- MGLD 44.8M
- SER 53.1M
- IPO Year
- MGLD N/A
- SER 2018
- Fundamental
- Price
- MGLD $1.07
- SER $5.07
- Analyst Decision
- MGLD
- SER Strong Buy
- Analyst Count
- MGLD 0
- SER 2
- Target Price
- MGLD N/A
- SER $13.00
- AVG Volume (30 Days)
- MGLD 15.1K
- SER 337.5K
- Earning Date
- MGLD 11-07-2025
- SER 11-11-2025
- Dividend Yield
- MGLD N/A
- SER N/A
- EPS Growth
- MGLD N/A
- SER N/A
- EPS
- MGLD N/A
- SER N/A
- Revenue
- MGLD $31,205,000.00
- SER $130,000.00
- Revenue This Year
- MGLD N/A
- SER N/A
- Revenue Next Year
- MGLD N/A
- SER N/A
- P/E Ratio
- MGLD N/A
- SER N/A
- Revenue Growth
- MGLD N/A
- SER N/A
- 52 Week Low
- MGLD $0.64
- SER $3.81
- 52 Week High
- MGLD $2.10
- SER $10.28
- Technical
- Relative Strength Index (RSI)
- MGLD 59.78
- SER 44.91
- Support Level
- MGLD $1.01
- SER $4.90
- Resistance Level
- MGLD $1.15
- SER $5.25
- Average True Range (ATR)
- MGLD 0.08
- SER 0.51
- MACD
- MGLD 0.01
- SER -0.01
- Stochastic Oscillator
- MGLD 75.00
- SER 11.21
About MGLD The Marygold Companies Inc.
The Marygold Companies Inc is a holding company that intends to focus on financial services. It is currently directing its investments towards financial services and the emerging Fintech space.
About SER Serina Therapeutics Inc.
Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers. The Company has one reportable segment relating to the research and development of its POZ platform.